(PRRT) of Gastro-Entero-Pancreatic NeuroEndocrine Tumors

More documents

Recommendations

Info

[ 177 Lu-DOTA 0 ,Tyr 3 ]Octreotate Therapy
[ 177 Lu-DOTA 0 ,Tyr 3 ]Octreotate Therapy: Nonfunctioning Tumor <strong>of</strong> the <strong>Pancreatic</strong> Tail • CT before and 6 weeks after the last treatment. Identical scaling. • The patient had lost > 15 kg bodyweight before the treatment, and regained 14 kg in the interval (8 months). • Note the decrease in tumor size and increase in body circumference.
Page 1 and 2: Molecular Medicine Same Molecule/Ta
Page 3: Targeted Radionuclide Therapy with
Page 7 and 8: Molecular Medicine of GEPNET Introd
Page 9 and 10: Cytoreductive therapies for inopera
Page 11 and 12: Structure of a Radiopeptide Recepto
Page 13 and 14: Molecular Imaging at ErasmusMC
Page 15 and 16: Molecular Medicine at ErasmusMC
Page 17 and 18: [ 177 Lu-DOTA 0 ,Tyr 3 ]Octreotate
Page 23: [ 177 Lu-DOTA 0 ,Tyr 3 ]Octreotate
Page 27 and 28: PRRT with LuTate in GEPNET shows an
Page 31 and 32: Future Developments for PRRT in GEP
Page 33 and 34: Radiolabelled [DOTA 0 ,Tyr 3 ]Octre
Page 35 and 36: Proof of Concept in Prostate Cancer

(PRRT) of Gastro-Entero-Pancreatic NeuroEndocrine Tumors

Create successful ePaper yourself

Delete template?

Save as template?